Final appeal for lung cancer drug1st May 2007
Following the decision by NICE in June 2006 not to recommend the drug Pemetrexed for the treatment of mesothelioma, a form of lung cancer linked to asbestos, the final appeal will now be heard in June to determine whether the decision will stand.
The NICE appeals process is part of a series of checks and balances to ensure the right decisions were made. NICE agreed to submit the decision to appeal in December when Eli Lilley, the drug's manufacturer, contested the decision.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Final appeal for lung cancer drug
Author: Chris May
Article Id: 2923
Date Added: 1st May 2007